Tumor Biology

, Volume 37, Issue 11, pp 14757–14764 | Cite as

Transcriptome sequencing of HER2-positive breast cancer stem cells identifies potential prognostic marker

  • Bo Lei
  • Xian-yu Zhang
  • Jia-peng Zhou
  • Guan-nan Mu
  • Yi-wen Li
  • You-xue Zhang
  • Da Pang
Original Article

Abstract

In cancer stem cell theory, breast cancer stem cells (BCSCs) are postulated to be the root cause of recurrence and metastasis in breast cancer. Discovery of new biomarkers and development of BCSC-targeted therapy are practical issues that urgently need to be addressed in the clinic. However, few breast cancer stem cell targets are known. Given that there are few BCSCs, performing transcriptome sequencing on them thus far has not been possible. With the emergence of single-cell sequencing technology, we have now undertaken such a study. We prepared single-cell suspensions, which were sorted using flow cytometry from breast tumor tissue and adjacent normal breast tissue from two HER2-positive patients. We obtained BCSCs, breast cancer cells, mammary cells, and CD44+ mammary cells. Transcriptome sequencing was then performed on these four cell types. Using bioinformatics, we identified 404 differentially expressed BCSC genes from the HER2-positive tumors and preliminary explored transcriptome characteristics of BCSCs. Finally, by querying a public database, we found that CA12 was a novel prognostic biomarker in HER2-positive breast cancer, which also had prognostic value in all breast cancer types. In conclusion, our results suggest that CA12 may be associated with BCSCs, especially HER2-positive BCSCs, and is a potential novel therapeutic target and biomarker.

Keywords

Breast cancer stem cell HER2-positive Transcriptome sequencing Biomarker 

Supplementary material

13277_2016_5351_MOESM1_ESM.xlsx (132 kb)
Table S1(XLSX 131 kb)

References

  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMedGoogle Scholar
  2. 2.
    Ajani JA, Song S, Hochster HS, Steinberg IB. Cancer stem cells: the promise and the potential. Semin Oncol. 2015;42 Suppl 1:S3–17.CrossRefPubMedGoogle Scholar
  3. 3.
    Iqbal J, Chong PY, Tan PH. Breast cancer stem cells: an update. J Clin Pathol. 2013;66:485–90.CrossRefPubMedGoogle Scholar
  4. 4.
    Krishnan P, Ghosh S, Wang B, Li D, Narasimhan A, Berendt R, et al. Next generation sequencing profiling identifies miR-574-3p and miR-660-5p as potential novel prognostic markers for breast cancer. BMC Genomics. 2015;16:735.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Sachlos E, Risueno RM, Laronde S, Shapovalova Z, Lee JH, Russell J, et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell. 2012;149:1284–97.CrossRefPubMedGoogle Scholar
  6. 6.
    Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983–8.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005;65:5506–11.CrossRefPubMedGoogle Scholar
  8. 8.
    Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006;8:R59.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2012;9:16–32.CrossRefGoogle Scholar
  10. 10.
    Oak PS, Kopp F, Thakur C, Ellwart JW, Rapp UR, Ullrich A, et al. Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells. Int J Cancer. 2012;131:2808–19.CrossRefPubMedGoogle Scholar
  11. 11.
    Lawson DA, Bhakta NR, Kessenbrock K, Prummel KD, Yu Y, Takai K, et al. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature. 2015;526:131–5.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012;7(3):562–578.Google Scholar
  13. 13.
    Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123:725–31.CrossRefPubMedGoogle Scholar
  14. 14.
    Muhammad E, Leventhal N, Parvari G, Hanukoglu A, Hanukoglu I, Chalifa-Caspi V, et al. Autosomal recessive hyponatremia due to isolated salt wasting in sweat associated with a mutation in the active site of Carbonic Anhydrase 12. Hum Genet. 2011;129:397–405.CrossRefPubMedGoogle Scholar
  15. 15.
    Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, et al. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell. 2011;147:759–72.CrossRefPubMedGoogle Scholar
  16. 16.
    Bhat MA, Al-Dhfyan A, Naglah AM, Khan AA, Al-Omar MA. Lead optimization of 2-Cyclohexyl-N-[(Z)-(3-methoxyphenyl/3-hydroxyphenyl) methylidene]hydrazinecarbothioamides for targeting the HER-2 overexpressed breast cancer cell line SKBr-3. Molecules. 2015;20:18246–63.CrossRefPubMedGoogle Scholar
  17. 17.
    Zhou M, Hou Y, Yang G, Zhang H, Tu G, Du YE, et al. LncRNA-Hh strengthen cancer stem cells generation in twist-positive breast cancer via activation of hedgehog signaling pathway. Stem Cells. 2016;34:55–66.CrossRefPubMedGoogle Scholar
  18. 18.
    Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007;11:259–73.CrossRefPubMedGoogle Scholar
  19. 19.
    Kobayashi M, Matsumoto T, Ryuge S, Yanagita K, Nagashio R, Kawakami Y, et al. CAXII Is a sero-diagnostic marker for lung cancer. PLoS One. 2012;7:e33952.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Chien MH, Ying TH, Hsieh YH, Lin CH, Shih CH, Wei LH, et al. Tumor-associated carbonic anhydrase XII is linked to the growth of primary oral squamous cell carcinoma and its poor prognosis. Oral Oncol. 2012;48:417–23.CrossRefPubMedGoogle Scholar
  21. 21.
    Yoo CW, Nam BH, Kim JY, Shin HJ, Lim H, Lee S, et al. Carbonic anhydrase XII expression is associated with histologic grade of cervical cancer and superior radiotherapy outcome. Radiat Oncol. 2010;5:101.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Eom KY, Jang MH, Park SY, Kang EY, Kim SW, Kim JH, et al. The expression of carbonic anhydrase (CA) IX/XII and lymph node metastasis in early breast cancer. Cancer Res Treat. 2015.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Bo Lei
    • 1
  • Xian-yu Zhang
    • 1
  • Jia-peng Zhou
    • 2
  • Guan-nan Mu
    • 3
  • Yi-wen Li
    • 4
  • You-xue Zhang
    • 1
  • Da Pang
    • 1
  1. 1.Department of Breast SurgeryHarbin Medical University Cancer HospitalHarbinChina
  2. 2.Department of Internal Medicine-NeurologyGeneral Hospital of Chinese People’s Armed Police ForcesBeijingChina
  3. 3.Department of Biotherapy CenterHarbin Medical University Cancer HospitalHarbinChina
  4. 4.Department of Medical OncologyThe Second Affiliated Hospital of Harbin Medical UniversityHarbinChina

Personalised recommendations